

## **RESEARCH CENTER FOR ACQUIRED IMMUNODEFICIENCY SYNDROME LABORATORY OF VIRAL PATHOGENESIS**

A long standing goal of our research group is to elucidate the molecular mechanisms of virus pathogenesis. We have been focusing on two human viruses, human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1).

### **1) Molecular analysis on interaction of hiv-1 and host factors: T. YOSHIDA, K. SATO, Y. SHINODA, T. KOBAYASHI, T. WATANABE, S. YAMAMOTO and Y. KOYANAGI**

Changing cellular protein trafficking may represent a novel antiviral approach. We have discovered that an N-terminal deletion mutant of a membrane protein, CD63, (CD63ΔN) blocks entry of CXCR4-using, T-cell tropic human immunodeficiency virus type 1 (X4 HIV-1) by suppressing CXCR4 surface expression. This suppression was observed in CXCR4 but not in CD4, CCR5, CD25, CD71, or other tetraspanin proteins. From a series of extensive analyses including confocal and total internal reflection fluorescence microscopy examination, the suppression of CXCR4 expression on the plasma membrane appeared to be caused by mislocalization of CXCR4 and exclusive transportation of CXCR4 toward intracellular organelles mainly the late endosomes/lysosomes. Our data suggest that CXCR4 trafficking is able to be modified in terms of its recruitment to the plasma membrane without enhancing the degradation or arresting vesicular transport of CXCR4 (*Traffic*, 9: 540–558, 2008). Furthermore, we found that wild type CD63 molecule was eliminated from the plasma membrane of HIV-1-producing T cell after activation, followed by a decrease in the amount of virion-incorporated CD63, and oppositely, an increase in the infectivity of the released virions. On the other hand, we found that CD63 at the cell surface was preferentially embedded on the membrane of released virions in HIV-1 envelope protein (Env)-independent manner, and that virion-incorporated CD63 had a potential to inhibit HIV-1 Env-mediated infection in a strain-specific manner at the post-attachment entry step(s). In addition, these behaviors were commonly observed in the other tetraspanin proteins, such as CD9, CD81, CD82 and CD231. However, L6 protein, which has similar topology with tetraspanins but does not belong to tetraspanin superfamily, did not have the potential to prevent HIV-1 infection, even though its successful incorporation into the released particles (*J. Virol.*, 82:1021-1033, 2008). Taken together, these results suggest that tetraspanin proteins commonly have a unique potential to modulate HIV-1 infectivity through incorporation into released HIV-1 particles, and our findings may provide a clue to elucidate uncovered aspects of HIV-1 entry. We are also attempting to identify HIV-associated host factors using a variety of

genetics- and protein chemistry-based methods. Candidate of the HIV-associated host factors under investigation are interferon, cytokines, signal molecules, and membrane proteins.

**2) HIV pathogenesis: K. SATO, N. MISAWA, J. CHUANYI NIE, H. KITAYAMA and Y. KOYANAGI**

We developed a small animal model in which human cells (peripheral blood lymphocytes, PBL) are transplanted into a T, B, and NK cell-deficient mouse (NOD/SCID/IL-2R<sup>γ</sup> null mouse, NOG mouse) strain created in collaboration with the Central Institute for Experimental Animals in Kanagawa. In the human PBL-transplanted mice (hu-PBL-NOG-SCID mouse), abundant human CD4 (hCD4) cell killing was reproduced with CCR5-using (R5) HIV-1 infection and HIV-1 induced a neuropathology that resembled HIV encephalopathy observed in human patients. Using the model, we have found that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not Fas-ligand (FasL) has critical contribution in the HIV-1-induced CD4<sup>+</sup> T cell bystander killing as well as neuronal apoptosis in the central nervous system (CNS) (*J. Exp. Med.* 193, 651-659, 2001, *Proc. Natl. Acad. Sci. USA.* 100, 2777-2782, 2003). TRAIL could therefore be a potential target for the therapeutic intervention of HIV-induced bystander cell killing in HIV-1-infected patients. However, the chimeric mice transplanted with human PBL are not fully reconstituted with human blood cells. Thus, we recently developed a novel human-chimera mouse model, NOG-hCD34 mice by transplanting newborn NOG mice with hCD34<sup>+</sup> cells via hepatic injection. The longitudinal flow cytometric analyses showed that NOG-hCD34 mice were able to support human hematopoiesis and multilineage differentiation of human leukocytes for at least 44 weeks. When infected with CCR5-tropic or CXCR4-tropic HIV-1, NOG-hCD34 mice reproduced HIV-1-associated complications such as intrathymic infection, sequential decrease in peripheral as well as splenic hCD4/hCD8 ratio and depletion of splenic hCD4<sup>+</sup>hCD45RA<sup>-</sup>hCCR5<sup>+</sup> T lymphocytes. High plasma HIV-1 RNA load was observed in CCR5-tropic HIV-1 infected mice for prolonged period of time. The infected mice were depleted in peripheral hCD45RA<sup>-</sup>hCD4<sup>+</sup> T lymphocytes, and there were marked peaks in the percentages of peripheral hCD45RA<sup>-</sup>hCD8<sup>+</sup> T lymphocytes after HIV-1 infection. In the splenic T lymphocytes positive for HIV-1 p24, severe down-regulation of hCD4 surface expression was observed. These data suggests that NOG-hCD34 mouse can have variety of application in long-lasting and systemic studies of HIV-1 pathogenesis, as well as in the testing of anti-HIV-1 drug candidates.

**3) Mechanism of Herpes virus and HIV-1 neuropathogenesis: H. KITAYAMA, A. ANDO and Y. KOYANAGI**

Herpes simplex virus type 1 (HSV-1) causes fatal and sporadic encephalitis in human. The encephalitis-survivors frequently suffer from symptoms of memory deficits. It remains unclear how HSV-1 induces tissue damages in memory formation-associated brain tissues such as the hippocampus. In this study, we examined HSV-1 infection in the hippocampus using a rat HSV-1 infection model. We found profound pathological changes in the hippocampus and large numbers of HSV-1 antigen-positive cells in the dentate gyrus (DG) subfield of HSV-1-infected rats. To understand the precise mechanism of HSV-1-induced tissue damages in the hippocampus, we employed rat organotypic hippocampal slice cultures (OHC) as an *in vitro* HSV-1 infection model. In OHC, HSV-1 infection predominated in neuronal cells and the infected neuronal cells were severely damaged. Longitudinal analysis indicated that granule cells in DG subfield were extremely vulnerable to HSV-1 infection among neuronal cells in the hippocampus (Microbes Infect. 10:1514-1523, 2008). Since DG granule cells play a crucial role in memory formation, disruption of these cells may be a primary step leading to memory deficits.

HIV-1-infected macrophages damage mature neurons in the brain, though their effect on neuronal development has not been clarified. We show that HIV-1-infected macrophages produce factors that impair development of neuronal precursor cells, and that soluble viral protein R (Vpr) is one of the factors which have the ability to suppress axonal growth. Cell biological analysis revealed that extracellularly administered recombinant Vpr (rVpr) clearly accumulated in mitochondria where a Vpr-binding protein adenine nucleotide translocator (ANT) localizes, and decreased mitochondrial membrane potential ( $\Delta\Psi_m$ ), which led to ATP synthesis. The depletion of ATP synthesis reduced transportation of mitochondria within neurites. This mitochondrial dysfunction inhibited axonal growth even when the frequency of apoptosis was not significant. We also found that point mutations of arginine (R) residues to alanines (A) residues at positions 73, 77, and 80 rendered rVpr incapable of causing mitochondrial membrane depolarization and axonal growth inhibition. Moreover, the Vpr-induced inhibition was suppressed after the treatment with ubiquinone analogue (ubiquinone-10). Our results suggest that soluble Vpr is a major viral factor that causes disturbance of neuronal development through induction of mitochondrial dysfunction. Since ubiquinone-10 protects the neuronal plasticity *in vitro*, it may be a therapeutic agent that can offer defense against HIV-1-associated neurological disease (*J. Virol.* 82: 2528-2542, 2008). Our results suggest that HSV-1 itself and HIV-1 Vpr are the major factors causing disturbance of neuronal cell development.

## **LIST OF PUBLICATIONS**

**Research Center for Acquired Immunodeficiency Syndrome**

**Laboratory of Viral Pathogenesis**

Sato, K., Aoki, J, Misawa, N., Daikoku, E., Sano, K, Tanaka, Y., and Koyanagi, Y. Modulation of

- human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. *J. Virol.* 82: 1021-1033, 2008.
- Kitayama, H., Miura, Y., Ando, Y., and Koyanagi, Y. Human immunodeficiency virus type-1 vulnerates nascent neuronal cells. *Microbiol. Immunol.* 52: 78-88, 2008.
- Koyanagi, Y., Tanaka, Y., Ito, M., and Yamamoto, N. Humanized mice for human retrovirus infection. "Humanized Mice", *Curr. Top. Microbiol. Immunol.* 324:133-148, 2008. Nomura, Tatsuji; Watanabe, Takeshi; Habu, Sonoko (Eds.).
- Yoshida, T., Kawano, Y., Sato, K., Ando, Y., Aoki, J., Miura, Y., Komano, J., Tanaka, Y., and Koyanagi, Y. A CD63 mutant inhibits T-cell tropic HIV-1 entry by disrupting CXCR4 trafficking to the plasma membrane. *Traffic* 9: 540-558, 2008.
- Kitayama, H., Miura, Y., Ando, Y., Hoshino, S., Ishizaka, Y., and Koyanagi, Y. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. *J. Virol.* 82: 2528-2542, 2008.
- Kawamura, T., Koyanagi, Y., Nakamura, Y., Ogawa, Y., Yamashita, A., Iwamoto, T., Ito, M., Blauvelt, A., and Shimada, S. Significant virus replication in Langerhans cells following application of HIV to abraded skin: Relevance to occupational transmission of HIV. *J. Immunol.* 180: 3297-3304, 2008.
- Yamaguchi, K., Sugiyama, T., Kato, S., Kondo, Y., Ageyama, N., Kanekiyo, M., Iwata, M., Koyanagi, Y., Yamamoto, N., and Honda, M. A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently. *J. Med. Virol.* 80:1322-1331, 2008.
- Urano, E., Kariya, Y., Futahashi, Y., Ichikawa, R., Hamatake, M., Fukazawa, H., Morikawa, Y., Yoshida, T., Koyanagi, Y., Yamamoto, N., and Komano, J. Identification of the P-TFb complex-interacting domain of Brd4 as an inhibitor of HIV-1 replication by functional cDNA library screening in MT-4 cells. *FEBS Lett.* 582:4053-4058, 2008.
- Ando, Y., Kitayama, H., Kawaguchi, Y., and Koyanagi, Y.. Primary target cells of herpes simplex virus type 1 in the hippocampus. *Microbes Infect.* 10:1514-1523, 2008.
- 小柳義夫、森川裕子、塩田達雄、高折晃史、増田貴夫、Paul Spearman. *J. AIDS Res. (日本エイズ学科誌)* :10(2), 79-84, 2008.
- 小柳義夫. 神経毒 HIV Vpr 蛋白. *医学のあゆみ*:226(11), 1010-1012, 2008.
- 小柳義夫. HIV の細胞特異性, *細胞* : 40(11), 454-457, 2008.
- 鈴木陽一、小柳義夫, エイズウイルス : 細胞とウイルスのせめぎあい, *細胞工学*:27(12), 1261-1268, 2008.
- 小柳義夫、2008 年ノーベル医学・生理学賞②エイズウイルス発見のおもてうら, *細胞工学*:27(12), 1285-1287, 2008.
- 佐藤佳, 小柳義夫. Sputnik Sweetheart – ウイルスに感染するウイルス. *ウイルス (日本ウイルス学会誌)*:58(2), 219-220, 2008.


- 
- Kitayama, H, Miura, Y., Ando, Y., Hoshino, S., Ishizaka, Y., and Koyanagi, Y. HIV-1 VPR in mitochondria impairs neuronal progenitor cell differentiation, Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Urano, E., Kariya, Y., Futahashi, Y., Hamatake, M., Morikawa, Y., Yoshida, T., Koyanagi, Y., Yamamoto, N., and Komano, J. Identification of the carboxy-terminal domain of bromodomain containing 4 as a specific silencer of HIV-1 replication, Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Yoshida, T., Kawano, Y., Ando, Y., Sato, K., Komano, J., Tanaka, Y., and Koyanagi, Y. A CD63 mutant inhibits CXCR4 trafficking to the plasma membrane and block X4 HIV-1 entry. Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Shinoda, Y., Suzuki, Y., Tanaka, Y., and Koyanagi, Y. Interferon- $\omega$ 1 is a powerful inhibitor for HIV-1 infection. Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Sato, K., Aoki, J., Misawa, N., Daikoku, E., Sano, K., Tanaka, Y., and Koyanagi, Y. Tetraspanin on HIV-1 virions modulates its infectivity. Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Yamamoto, S., Okawa, K., Masuda, T., Koyanagi, Y., and Suzuki, Y. Identification of cellular interactors to MoMLV integrase using tandem affinity purification-mass spectrometry analysis. Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Urano, E., Kariya, Y., Futahashi, Y., Hamatake, M., Morikawa, Y., Yoshida, T., Koyanagi, Y., Yamamoto, N., and Komano, J. Identification of the carboxy-terminal domain of bromodomain containing 4 as a specific silencer of HIV-1 replication. Retroviruses Meeting, Cold Spring Harbor, New York, 2008.
- Ando, Y., Kitayama, H., Kawaguchi, Y., and Koyanagi, Y. Primary target cells of herpes simplex virus type 1 in the hippocampus. The 15th East Asia Joint Conference on Biomedical Research, Seoul, 2008.
- Kitayama, H., Ando, Y., Hoshino, S., Ishizaka, Y., and Koyanagi, Y. HIV-1 Vpr in Mitochondria impairs neuronal cell repair. XIV. International Congress of Virology, Istanbul, 2008.
- Yoshida, T., Kawano, Y., Ando, Y., Sato, K., Komano, J., Tanaka, Y., and Koyanagi, Y. CD63 and its mutants inhibit fusion of CXCR4-containing vesicles to the plasma membrane and block X4 HIV-1 entry. XIII IUMS International Congress of Virology, Istanbul, 2008.
- Suzuki, Y., Ogawa, K., Koyanagi, Y., and Suzuki, Y. VRK induces dysfunction of the MoMLV PIC through phosphorylation of BAF. 3rd International Conference on Retroviral Integrase, Woods hole, Massachusetts, 2008.
- Koyanagi, Y.: HIV and AIDS 日中数理生物学コロキウムシンポジウム、岡山, 2008.
- Koyanagi, Y.: HIV-1 pathogenesis: productive infection in CD4+ effector memory T lymphocytes

- and CD4+ depletion in humanized mice, 第 11 回京都大学国際シンポジウム、上海, 2008.
- Sato, K., Nie, C., Misawa, N., Tanaka, Y., Ito, M., and Koyanagi, Y. Characterization of HIV-1 pathogenesis and the infected cells in humanized mice. 16th Conference on Retroviruses and Opportunistic Infections, D-179, Montreal, 2009.
- Sato, K., Aoki, J., Misawa, N., Daikoku, E., Sano, K., Tanaka, Y., and Koyanagi, Y. Modulation of HIV-1 infectivity through incorporation of tetraspanin proteins. The Kinki AIDS Seminar, Nara, 2008.
- Sato, K., Nie, C., Misawa, N., Tanaka, Y., Ito, M., and Koyanagi, Y. Characterization of pathogenesis and productive infection of HIV-1 in humanized mice. The 8th Awaji Symposium, Awaji, 2008.
- Yamamoto, S., Okawa, K., Masuda T., Koyanagi, Y., and Suzuki, Y. Functional association of HIV-1 and MoMLV integrase with HECT-domain ubiquitin ligase Huwe1. The 9th Kumamoto AIDS Seminar, Kumamoto, 2008.
- 渡部匡史, 鈴木陽一, 宮澤正顯, 小柳義夫: Small GTPase Rac2 による HIV-1 増殖制御. 第 56 回日本ウイルス学会, 岡山, 2008.
- 鈴木康嗣, 小川加那子, 小柳義夫, 鈴木陽一: 細胞性キナーゼ VRK1 によるレトロウイルスインテグレーション機能の阻害とその分子メカニズム. 第 56 回日本ウイルス学会, 岡山, 2008.
- 篠田康彦, 鈴木陽一, 田中勇悦, 小柳義夫: インターフェロンオメガ 1 による HIV-1 感染抑制機構の解析. 第 22 回日本エイズ学会、大阪、2008.
- 安藤良徳, 北山裕子, 小柳義夫: ウイルスに対する海馬組織の脆弱性に関する研究. 第 22 回日本エイズ学会、大阪、2008.
- 小林 朋子, 芳田 剛, 駒野 淳, 小柳 義夫: レンチウイルスベクターを用いた抗 HIV 因子のスクリーニングとその解析. 第 22 回日本エイズ学会、大阪、2008.
- 佐藤佳, Chuanyi Nie, 三沢尚子, 田中勇悦, 伊藤守, 小柳義夫: ヒト化マウスにおける HIV-1 感染指向性と持続感染細胞の同定. 第 22 回日本エイズ学会, 大阪, 2008.
- 渡部匡史, 鈴木陽一, 宮澤正顯, 小柳義夫: HIV-1 複製制御における Small GTPase Rac2 の機能解析. 第 22 回日本エイズ学会, 大阪, 2008.
- 山元誠司, 大川克也, 小川加那子, 増田貴夫, 森川裕子, 小柳義夫, 鈴木陽一: TAP-MS 法によるインテグラーゼ結合因子 Huwe1 の同定とその解析. 第 22 回日本エイズ学会、大阪、2008.
- 佐藤佳, 三沢尚子, Chuanyi Nie, 高橋玲, 伊藤守, 小柳義夫: EBV 感染モデルマウスの確立と活性化 CD8<sup>+</sup>T 細胞の誘導. 第 38 回日本免疫学会総会, 京都, 2008.


北山裕子が平成 20 年 3 月に医学研究科博士課程を修了・学位を取得し、大鵬薬品に入社した。平成 20 年 4 月に生命科学研究科修士課程に横山貴章が入学した。8 月に Johnny Chuanyi Nie がカナダ British Columbia 大学に復学した。11 月 26 日から 28 日に第 22 回日本エイズ学会総会・学術総会を開催した。

以下の 3 つのテーマについて研究を遂行している。

1) HIV 感染に関わる宿主因子の解析 : HIV を改良したレンチウイルスベクターを用いて HIV 感受性細胞に cDNA ライブラリを発現させ、HIV 感染に耐性を賦与する遺伝子探索実験系を確立した(*J. Virol.* 78, 11352-11359, 2004)。これにより、CD63 の N 末端欠損 変異体(CD63ΔN)が、CXCR4 のゴルジ体から細胞質膜への移動を特異的に抑制することを見出した(芳田ら、*Traffic*, 9: 540-558, 2008)。さらに、CD63 と同じ分子群に分類される CD9, CD81, CD82, CD231 などのテトラスパニン分子は、ウイルス粒子のエンベロープに取り込まれ、このウイルス粒子の標的細胞との結合後の侵入過程を抑制すること、そして、この抑制作用はウイルス分離株特異的であることを見出した(佐藤ら、*J. Virol.*, 82:1021-1033, 2008)。これらの結果は、テトラスパニン分子がウイルス感染を抑制する活性を有することを示している(下図)。テトラスパニンに加え、遺伝学的ならびに蛋白質化学的手法により、新規 HIV 関連宿主因子の探索研究を行っている。現在、その候補分子として解析を行っているのは、インターフェロン、サイトカイン、シグナル分子、ユビキチン関連分子、膜蛋白質などである。(芳田剛、佐藤佳、篠田康彦、山元誠司、小林朋子、渡部匡史、小柳義夫)



2) HIV 病原性解析：神奈川の実験動物中央研究所との共同研究により T, B, NK 細胞欠損マウス (NOG マウス) にヒト末梢血リンパ球を移植し、HIV 感受性マウスモデルを確立した。このモデルマウス (hu-PBL-NOG mouse) では、CCR5 を補受容体とする R5 HIV-1 の感染により CD4 細胞の破壊と中枢神経内の神経細胞の細胞死を引き起こすことができる。そして、これらの細胞死は Fas ligand でなく、TRAIL を介することがわかった(*J. Exp. Med.* 193, 651-659, 2001, *Proc. Natl. Acad. Sci. USA.* 100, 2777-2782, 2003)。すなわち、TRAIL に対する抑制薬は、エイズ患者に対する細胞障害治療薬となりうる可能性を示唆している。しかしながら、これらの末梢血移植マウスでは、すべての血液系細胞が構築されているのではない。そこで、新生児 NOG マウスの肝臓内にヒト CD34 陽性血液幹細胞を移植するヒト化マウスモデル(NOG-hCD34)を作製した(下図)。このマウスのなかでは、ヒト長期造血能、ならびに、リンパ球、マクロファージ、樹状細胞への分化増殖能が少なくとも 44 週間は維持された。そして、HIV 感染により胸腺細胞の破壊、末梢血ならびに脾臓における CD4/CD8 比の減少、そして、CD4 陽性 CD45 陰性 CCR5 陽性 T 細胞の欠乏が観察された。長期にわたる高ウイルス血症が R5 ウイルス感染により誘導され、CD45 陰性 CD4 陽性 T 細胞の減少と CD45 陰性 CD8 陽性 T 細胞の一過性の増加も観察された。さらに、脾臓内の HIV 抗原(p24)陽性細胞では、細胞表面上 CD4 分子の発現が極端に減少していた(投稿中)。これらの結果は、NOG-hCD34 マウスが、HIV 持続感染モデルならびに抗 HIV 候補薬の評価実験系となりうることを示唆している。(佐藤佳、三沢尚子、Johnny Chuanyi Nie, 北山裕子、小柳義夫)





3) ヘルペスウイルスならびに HIV 脳炎の発症メカニズム：ラット海馬培養スライス片に GFP 発現 HSV（東京大学川口博士との共同研究により入手）を感染させると、このウイルスの感染播種の過程を観察できることがわかった。特に、神経幹細胞が局在し、それらの細胞分化が活発な海馬歯状回に対して HSV は強力な細胞障害を引き起こし、神経グリアの組織構成を破壊することがわかった(*Microbes Infect.* 10:1514-1523, 2008)。同じスライス培養法を用いて、HIV 感染マクロファージが神経細胞分化を抑制する因子を遊離していることを見出した（北山ら、*Microbiol. Immunol.* 52: 78-88, 2008, 下図左）。そして、その中で HIV がコードする Vpr 蛋白質が軸索伸長障害作用を有することがわかった。神経分化培養細胞に組換え Vpr 蛋白質を添加すると、ANT という Vpr 結合性蛋白質が局在するミトコンドリア分画にすばやく移行し、ミトコンドリアの膜電位低下、そして、ATP 産生を抑制する。さらにその ATP 産生低下が神経樹状突起のミトコンドリアへの移行を抑制する結果、軸索は伸長できないことがわかった (*J. Virol.* 82: 2528-2542, 2008, 下図右)。これらの結果は、HSV それ自身ならびに HIV Vpr 蛋白質は神経細胞分化障害の主要因となっていることを示唆するものである。（北山裕子、安藤良徳、横山貴章、小柳義夫）

